Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Issue 8 (August 2016)

• Record Type: Journal Article
• Authors: Arendt-Nielsen, Lars; Egsgaard, Line Lindhardt; Petersen, Kristian Kjær
• Is Part Of: Pain. Volume 157:Issue 8(2016)
• Publication Date: 2016-08
• Subjects: Pressure pain thresholds -- Spreading sensitization -- Temporal summation -- CPM -- Descending pain modulation -- Osteoarthritis -- Pain -- Etoricoxib -- COX-2 inhibitor; Pain -- Periodicals; Douleur -- Périodiques; Anesthésie -- Périodiques; Pain; Electronic journals; Periodicals; Electronic journals; 616.0472
• DOI: 10.1097/j.pain.0000000000000562
• Languages: English
• ISSNs: 0304-3959

Abstract

Abstract : Abstract: The COX-2 inhibitor etoricoxib modulates the peripheral and central nociceptive mechanisms in animals. This interaction has not been studied in patients with pain. This randomized, double-blind, placebo-controlled, 2-way crossover, 4-week treatment study investigated the pain mechanisms modulated by etoricoxib in patients with painful knee osteoarthritis. Patients were randomized to group A (60 mg/d etoricoxib followed by placebo) or B (placebo followed by 60 mg/d etoricoxib). The quantitative, mechanistic pain biomarkers were pressure pain thresholds, temporal summation (TS), and conditioning pain modulation. Clinical readouts were Brief Pain Inventory, WOMAC, painDETECT questionnaire (PD-Q), and time and pain intensity during walking and stair climbing. Etoricoxib as compared with placebo significantly modulated the pressure pain thresholds ( P = 0.012, localized sensitization) at the knee and leg (control site) ( P = 0.025, spreading sensitization) and TS assessed from the knee ( P = 0.038) and leg ( P = 0.045). Conditioning pain modulation was not modulated. The Brief Pain Inventory (pain scores), PD-Q, WOMAC, and walking and stair climbing tests were all significantly improved by etoricoxib. Based on a minimum of 30% or 50% pain alleviation (day 0-day 28), responders and nonresponders were defined. The nonresponders showed a significant association between increased facilitation of TS and increased pain alleviation. None of the other parameters predicted the degree of pain alleviation. Generally, a responder to etoricoxib has the most facilitated TS. In conclusion, etoricoxib (1) modulated central pain modulatory mechanisms and (2) improved pain and function in painful osteoarthritis. Stronger facilitation of TS may indicate a better response to etoricoxib, supporting the central mode-of-action of the drug. Abstract : Etoricoxib significantly modulates peripheral/central sensitization and temporal summation in patients with painful knee osteoarthritis.